Development of ultra‐sensitive and reproducible measurement system for blood biomarkers

Background Neurodegenerative diseases, such as Alzheimer’s disease(AD), have become more prevalent in aging societies. Therefore, it is important to develop a blood‐based measurement system to diagnose early‐stage AD. However, such AD‐related biomarkers in blood exist at extremely low levels and are...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2024-12, Vol.20 (S2), p.n/a
Hauptverfasser: Tosaka, Kenta, Shimizu, Keisuke, Matsunaga, Taichi, Satou, Hiroshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue S2
container_start_page
container_title Alzheimer's & dementia
container_volume 20
creator Tosaka, Kenta
Shimizu, Keisuke
Matsunaga, Taichi
Satou, Hiroshi
description Background Neurodegenerative diseases, such as Alzheimer’s disease(AD), have become more prevalent in aging societies. Therefore, it is important to develop a blood‐based measurement system to diagnose early‐stage AD. However, such AD‐related biomarkers in blood exist at extremely low levels and are difficult to detect precisely and reproducibly. Method The measurement system was constructed by using brain natriuretic peptide(BNP) as a model biomarker. The outline of the system is as follows. (1) BNP in sample is captured by anti‐BNP antibody modified magnetic beads followed by enzyme labeling. (2) Magnetic beads with capturing BNP are enclosed in a microwell array for ultra‐sensitive detection of the marker. In our method, multiple beads are enclosed in a microwell to measure as many beads as possible and improve measurement reproducibility. (3) BNP is quantified by integrating the fluorescence intensity which generated by the enzymatic reaction in each microwells. BNP standards were measured in triplicate by developed system and calculated the limit of detection (LOD). Result The LOD of BNP was 2.5 fM (8.6 fg/mL), which was significantly sensitive compared to the conventional immunoassay system. Furthermore, the coefficient of variation (CV) of 7.2 fM (25 fg/mL) BNP was 8.1%, so that reproducibility in the low concentration range was also satisfactory. Conclusion We developed ultra‐sensitive and reproducible measurement system and it can be applied to the detection of AD‐related biomarkers in blood.
doi_str_mv 10.1002/alz.083956
format Article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ALZ083956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1696-f8b32de1585f29615ec7644ef783acb8fbccc615c7c6c0a3c74542461b7a7d383</originalsourceid><addsrcrecordid>eNp9kM1KxDAUhYMoOI5ufIKshY5J2zTtSobxFwbc6EI3IUlvNZo2JWlHxpWP4DP6JFY7DLhxdS_3nnM4fAgdUzKjhMSn0r7PSJ4ULNtBE8pYHLGYF7vbPSP76CCEF0JSklM2QQ_nsALr2hqaDrsK97bz8uvjM0ATTGdWgGVTYg-td2WvjbKAa5Ch9_DrCOvQQY0r57GyzpVYGVdL_wo-HKK9StoAR5s5RfeXF3eL62h5e3WzmC8jTbMii6pcJXEJlOWsiouMMtA8S1OoeJ5IrfJKaa2Hs-Y600QmmqcsjdOMKi55meTJFJ2NuW2vaij1UMtLK1pvhiJr4aQRfz-NeRZPbiUo5TQdWA0JJ2OC9i4ED9XWTIn4wSoGrGLEOojpKH4zFtb_KMV8-bjxfAP96n7x</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development of ultra‐sensitive and reproducible measurement system for blood biomarkers</title><source>Wiley Online Library Open Access</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Tosaka, Kenta ; Shimizu, Keisuke ; Matsunaga, Taichi ; Satou, Hiroshi</creator><creatorcontrib>Tosaka, Kenta ; Shimizu, Keisuke ; Matsunaga, Taichi ; Satou, Hiroshi</creatorcontrib><description>Background Neurodegenerative diseases, such as Alzheimer’s disease(AD), have become more prevalent in aging societies. Therefore, it is important to develop a blood‐based measurement system to diagnose early‐stage AD. However, such AD‐related biomarkers in blood exist at extremely low levels and are difficult to detect precisely and reproducibly. Method The measurement system was constructed by using brain natriuretic peptide(BNP) as a model biomarker. The outline of the system is as follows. (1) BNP in sample is captured by anti‐BNP antibody modified magnetic beads followed by enzyme labeling. (2) Magnetic beads with capturing BNP are enclosed in a microwell array for ultra‐sensitive detection of the marker. In our method, multiple beads are enclosed in a microwell to measure as many beads as possible and improve measurement reproducibility. (3) BNP is quantified by integrating the fluorescence intensity which generated by the enzymatic reaction in each microwells. BNP standards were measured in triplicate by developed system and calculated the limit of detection (LOD). Result The LOD of BNP was 2.5 fM (8.6 fg/mL), which was significantly sensitive compared to the conventional immunoassay system. Furthermore, the coefficient of variation (CV) of 7.2 fM (25 fg/mL) BNP was 8.1%, so that reproducibility in the low concentration range was also satisfactory. Conclusion We developed ultra‐sensitive and reproducible measurement system and it can be applied to the detection of AD‐related biomarkers in blood.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.083956</identifier><language>eng</language><publisher>Hoboken: John Wiley and Sons Inc</publisher><subject>Biomarkers</subject><ispartof>Alzheimer's &amp; dementia, 2024-12, Vol.20 (S2), p.n/a</ispartof><rights>2024 The Alzheimer's Association. published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714839/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714839/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,11543,27903,27904,45553,45554,46030,46454,53769,53771</link.rule.ids></links><search><creatorcontrib>Tosaka, Kenta</creatorcontrib><creatorcontrib>Shimizu, Keisuke</creatorcontrib><creatorcontrib>Matsunaga, Taichi</creatorcontrib><creatorcontrib>Satou, Hiroshi</creatorcontrib><title>Development of ultra‐sensitive and reproducible measurement system for blood biomarkers</title><title>Alzheimer's &amp; dementia</title><description>Background Neurodegenerative diseases, such as Alzheimer’s disease(AD), have become more prevalent in aging societies. Therefore, it is important to develop a blood‐based measurement system to diagnose early‐stage AD. However, such AD‐related biomarkers in blood exist at extremely low levels and are difficult to detect precisely and reproducibly. Method The measurement system was constructed by using brain natriuretic peptide(BNP) as a model biomarker. The outline of the system is as follows. (1) BNP in sample is captured by anti‐BNP antibody modified magnetic beads followed by enzyme labeling. (2) Magnetic beads with capturing BNP are enclosed in a microwell array for ultra‐sensitive detection of the marker. In our method, multiple beads are enclosed in a microwell to measure as many beads as possible and improve measurement reproducibility. (3) BNP is quantified by integrating the fluorescence intensity which generated by the enzymatic reaction in each microwells. BNP standards were measured in triplicate by developed system and calculated the limit of detection (LOD). Result The LOD of BNP was 2.5 fM (8.6 fg/mL), which was significantly sensitive compared to the conventional immunoassay system. Furthermore, the coefficient of variation (CV) of 7.2 fM (25 fg/mL) BNP was 8.1%, so that reproducibility in the low concentration range was also satisfactory. Conclusion We developed ultra‐sensitive and reproducible measurement system and it can be applied to the detection of AD‐related biomarkers in blood.</description><subject>Biomarkers</subject><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp9kM1KxDAUhYMoOI5ufIKshY5J2zTtSobxFwbc6EI3IUlvNZo2JWlHxpWP4DP6JFY7DLhxdS_3nnM4fAgdUzKjhMSn0r7PSJ4ULNtBE8pYHLGYF7vbPSP76CCEF0JSklM2QQ_nsALr2hqaDrsK97bz8uvjM0ATTGdWgGVTYg-td2WvjbKAa5Ch9_DrCOvQQY0r57GyzpVYGVdL_wo-HKK9StoAR5s5RfeXF3eL62h5e3WzmC8jTbMii6pcJXEJlOWsiouMMtA8S1OoeJ5IrfJKaa2Hs-Y600QmmqcsjdOMKi55meTJFJ2NuW2vaij1UMtLK1pvhiJr4aQRfz-NeRZPbiUo5TQdWA0JJ2OC9i4ED9XWTIn4wSoGrGLEOojpKH4zFtb_KMV8-bjxfAP96n7x</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Tosaka, Kenta</creator><creator>Shimizu, Keisuke</creator><creator>Matsunaga, Taichi</creator><creator>Satou, Hiroshi</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202412</creationdate><title>Development of ultra‐sensitive and reproducible measurement system for blood biomarkers</title><author>Tosaka, Kenta ; Shimizu, Keisuke ; Matsunaga, Taichi ; Satou, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1696-f8b32de1585f29615ec7644ef783acb8fbccc615c7c6c0a3c74542461b7a7d383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomarkers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tosaka, Kenta</creatorcontrib><creatorcontrib>Shimizu, Keisuke</creatorcontrib><creatorcontrib>Matsunaga, Taichi</creatorcontrib><creatorcontrib>Satou, Hiroshi</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alzheimer's &amp; dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tosaka, Kenta</au><au>Shimizu, Keisuke</au><au>Matsunaga, Taichi</au><au>Satou, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of ultra‐sensitive and reproducible measurement system for blood biomarkers</atitle><jtitle>Alzheimer's &amp; dementia</jtitle><date>2024-12</date><risdate>2024</risdate><volume>20</volume><issue>S2</issue><epage>n/a</epage><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Background Neurodegenerative diseases, such as Alzheimer’s disease(AD), have become more prevalent in aging societies. Therefore, it is important to develop a blood‐based measurement system to diagnose early‐stage AD. However, such AD‐related biomarkers in blood exist at extremely low levels and are difficult to detect precisely and reproducibly. Method The measurement system was constructed by using brain natriuretic peptide(BNP) as a model biomarker. The outline of the system is as follows. (1) BNP in sample is captured by anti‐BNP antibody modified magnetic beads followed by enzyme labeling. (2) Magnetic beads with capturing BNP are enclosed in a microwell array for ultra‐sensitive detection of the marker. In our method, multiple beads are enclosed in a microwell to measure as many beads as possible and improve measurement reproducibility. (3) BNP is quantified by integrating the fluorescence intensity which generated by the enzymatic reaction in each microwells. BNP standards were measured in triplicate by developed system and calculated the limit of detection (LOD). Result The LOD of BNP was 2.5 fM (8.6 fg/mL), which was significantly sensitive compared to the conventional immunoassay system. Furthermore, the coefficient of variation (CV) of 7.2 fM (25 fg/mL) BNP was 8.1%, so that reproducibility in the low concentration range was also satisfactory. Conclusion We developed ultra‐sensitive and reproducible measurement system and it can be applied to the detection of AD‐related biomarkers in blood.</abstract><cop>Hoboken</cop><pub>John Wiley and Sons Inc</pub><doi>10.1002/alz.083956</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-5260
ispartof Alzheimer's & dementia, 2024-12, Vol.20 (S2), p.n/a
issn 1552-5260
1552-5279
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714839
source Wiley Online Library Open Access; Wiley Online Library Journals Frontfile Complete; PubMed Central; PubMed Central Open Access
subjects Biomarkers
title Development of ultra‐sensitive and reproducible measurement system for blood biomarkers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A55%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20ultra%E2%80%90sensitive%20and%20reproducible%20measurement%20system%20for%20blood%20biomarkers&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Tosaka,%20Kenta&rft.date=2024-12&rft.volume=20&rft.issue=S2&rft.epage=n/a&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.083956&rft_dat=%3Cwiley_pubme%3EALZ083956%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true